Ventyx Biosciences’ (VTYX) “Neutral” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their neutral rating on shares of Ventyx Biosciences (NASDAQ:VTYX) in a research report released on Thursday morning, Benzinga reports. They currently have a $6.00 target price on the stock.

Other equities research analysts have also issued reports about the company. Lifesci Capital upgraded Ventyx Biosciences from a market perform rating to an outperform rating in a report on Wednesday, February 28th. Wells Fargo & Company raised Ventyx Biosciences from an equal weight rating to an overweight rating and boosted their price target for the stock from $7.00 to $16.00 in a research report on Tuesday, March 12th. Canaccord Genuity Group cut their price objective on Ventyx Biosciences from $16.00 to $15.00 and set a buy rating on the stock in a research note on Wednesday, March 13th. Finally, Oppenheimer upgraded Ventyx Biosciences from a market perform rating to an outperform rating and set a $12.00 target price for the company in a report on Tuesday, March 12th. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of Moderate Buy and a consensus target price of $15.75.

Ventyx Biosciences Price Performance

VTYX stock opened at $3.26 on Thursday. The company’s 50 day simple moving average is $4.57 and its 200-day simple moving average is $4.09. Ventyx Biosciences has a 52-week low of $1.87 and a 52-week high of $40.58. The firm has a market capitalization of $229.83 million, a P/E ratio of -1.01 and a beta of 0.58.

Ventyx Biosciences (NASDAQ:VTYX) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.62) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.05. During the same period in the previous year, the company posted ($0.68) EPS. Sell-side analysts predict that Ventyx Biosciences will post -2.31 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of VTYX. Tower Research Capital LLC TRC boosted its position in shares of Ventyx Biosciences by 1,424.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 19,927 shares of the company’s stock valued at $49,000 after acquiring an additional 18,620 shares in the last quarter. Federated Hermes Inc. acquired a new position in shares of Ventyx Biosciences in the 4th quarter worth approximately $50,000. Norden Group LLC bought a new position in shares of Ventyx Biosciences during the 1st quarter worth approximately $59,000. China Universal Asset Management Co. Ltd. grew its position in Ventyx Biosciences by 66.6% in the first quarter. China Universal Asset Management Co. Ltd. now owns 11,385 shares of the company’s stock valued at $63,000 after acquiring an additional 4,553 shares during the period. Finally, Aigen Investment Management LP acquired a new stake in shares of Ventyx Biosciences during the 4th quarter worth about $65,000. 97.88% of the stock is owned by institutional investors.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.